Immutep Limited

IMM

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Better Future Fund

IMPQ

IMPQ.AX was created on 2021-09-29 by Perennial. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to deliver long-term capital growth predominately through investments in Australian and New Zealand listed smaller and mid-cap companies that are Better Future Investments.

Imexhs Limited

IME

ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales and currently employs 400 full-time employees. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.

Infinity Mining Limited

IMI

Infinity Mining Ltd. engages in the exploration and development of gold, copper, base metals and lithium mineral properties. The firm holds a 100% interest in 10 exploration licenses, two mining leases and seven prospecting licenses in the Pilbara and Central Goldfields regions of Western Australia. The 711 square kilometer tenements are located in prospective gold-copper and lithium regions. The Panorama Project encompasses exploration licenses E45/4732, E454764 and E45/4779 held by the Company, covering a total of approximately 252 square kilometers. The Panorama Project is located 135 kilometers southeast of Port Headland in the Pilbara Region of Western Australia. The Tambourah North Project (E45/5324) is located approximately eight kilometers north of the Woody Project. The project covers a structural deformed section of a greenstone belt containing mafic and ultramafic rocks of the Euro Basalt. The Central Goldfields tenements are prospective for orogenic gold systems, copper-rich VMS systems and rare earth elements.